SafeHeal(R) Closes Oversubscribed €35 Million Series C Equity Financing

May 6, 2025 8:00 AM

SafeHeal®, a leading innovator in the field of colorectal cancer surgery, today announced a successful completion of an oversubscribed €35 million Series C equity financing to validate the use of Colovac®, a groundbreaking temporary endoluminal fecal bypass system. Colovac is intended as an alternative to temporary diverting ostomy for patients undergoing colorectal cancer resection. The proceeds leave SafeHeal well-funded to complete its IDE...

Read more

CBD Life Sciences Inc. (CBDL) Announces New Manufacturing Deal With A Southwest-Based Company

May 6, 2025 8:00 AM

CBD Life Sciences Inc. (OTC PINK:CBDL), a leading innovator in the CBD health and wellness space, is proud to announce a new strategic manufacturing partnership with Jeannie in a Bottle, a fast-growing Arizona-based CBD company with a national retail footprint.This powerful collaboration will see CBDL formulating and manufacturing top-tier CBD products for Jeannie in a Bottle - a company with proven market traction and shelf presence in over 100...

Read more

Tribun Health Achieves ISO/IEC 27001 Certification, Strengthening Commitment to Data Security in Digital Pathology

May 6, 2025 8:00 AM

Tribun Health, a leader in digital pathology software and AI-powered diagnostic solutions, is proud to announce that it has been awarded the ISO/IEC 27001 certification-an internationally recognized standard for information security management systems (ISMS).This achievement underscores Tribun Health's ongoing commitment to the highest standards of data protection, patient confidentiality, and operational excellence. In a field where security...

Read more

Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization

May 6, 2025 8:00 AM

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced new data showing that people hospitalized due to overt hepatic encephalopathy (OHE) had a reduced risk of OHE-related rehospitalization within 30 days if treated with Xifaxan® (rifaximin) following hospital discharge regardless of prior treatment. These findings,...

Read more

Boditech Med and SphingoTec Announce Launch of AFIAS penKid(R) Assay for Kidney Function Diagnostics

May 6, 2025 4:20 AM

Boditech Med Inc. ("Boditech") and SphingoTec GmbH ("SphingoTec") today announced the commercial launch of the AFIAS sphingotest® penKid® assay. The assay is designed to provide clinicians with a tool for assessing kidney function in critically ill patients by measuring Proenkephalin A 119-159 (penKid), a biomarker that reflects real-time kidney function independently of inflammation or comorbidities.The AFIAS sphingotest® penKid® assay is...

Read more

Accumax Unlocks Citation Visibility and Expands Reach Through Bioz Partnership

May 6, 2025 4:00 AM

Bioz, Inc., a leader in AI-powered scientific literature analysis and product validation, is proud to highlight the successful adoption of Bioz Badges by Accumax Lab Devices, a global manufacturer of high-precision liquid handling instruments and laboratory solutions. This partnership marks a pivotal step forward for Accumax, providing researchers with easy access to real publication data while equipping the company with essential tools to track...

Read more

Cantargia’s Announces Publication of Clinical Data Demonstrating Potential of Nadunolimab Plus Pembrolizumab in Solid Tumors

May 6, 2025 2:00 AM

Cantargia (STO:CANTA)Results published in the peer-reviewed journal Investigational New DrugsStudy in heavily pre-treated patients with solid tumor indications who had progressed on prior immune checkpoint inhibitorsMedian overall survival of 19.7 months, with greatest survival benefit in patients with high baseline levels of infiltrating immune cells in the tumor microenvironmentCantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced...

Read more

Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment

May 6, 2025 1:20 AM

Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced its financial results for Q1 2025, highlighting progress in strategic partnerships and implementation of measures to generate sustainable profitable growth.Dr Christian Wojczewski, Chief Executive Officer of Evotec, said:"With € 200 m of revenues we ended Q1 2025 slightly ahead of our expectation, despite a soft drug discovery market...

Read more

IRLAB: Invitation to the Interim Report for Q1 2025 Presentation and Webcast

May 6, 2025 1:20 AM

IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, May 6, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January - March 2025. The interim report will be published on Wednesday, May 7 at 07:00 CEST.The presentation...

Read more

NHI Issues Investor Update

May 5, 2025 4:15 PM

National Health Investors, Inc. (NYSE:NHI) has issued the following investor update which can be found at:https://investors.nhireit.com/News/presentations-and-webcasts/default.aspxAbout NHIIncorporated in 1991, National Health Investors, Inc. (NYSE: NHI) is a real estate investment trust specializing in sale, leasebacks, joint-ventures, senior housing operating partnerships, and mortgage and mezzanine financing of need-driven and discretionary...

Read more

NHI Announces Second Quarter 2025 Dividend

May 5, 2025 4:15 PM

National Health Investors, Inc. (NYSE:NHI) announced today that it will pay its second quarter dividend of $0.90 per common share on August 1, 2025, to stockholders of record as of June 30, 2025.About NHIIncorporated in 1991, National Health Investors, Inc. (NYSE: NHI) is a real estate investment trust specializing in sale, leasebacks, joint-ventures, senior housing operating partnerships, and mortgage and mezzanine financing of need-driven and...

Read more

NHI Announces First Quarter 2025 Results

May 5, 2025 4:05 PM

National Health Investors, Inc. (NYSE:NHI) announced today its results for the three months ended March 31, 2025.Financial Results and Recent EventsNet income attributable to common stockholders per diluted common share for the three months ended March 31, 2025 was $0.74 compared to $0.71 during the same period in the prior year. Net income attributable to common stockholders for the three months ended March 31, 2025 includes approximately $0.3...

Read more

Payer-Provider Collaboration Breakdown: Black Book Survey Reveals Critical Challenges in Healthcare Alignment

May 5, 2025 3:30 PM

A new survey from Black Book Research reveals that deep fractures remain in payer-provider collaboration, with hospitals and health plans struggling to align on core priorities like prior authorization, data exchange, and value-based contracting.The report, released today, draws on first-quarter responses from 273 executives across the healthcare spectrum, including 225 leaders from health plans, managed care organizations, and payers, and 48...

Read more

Genomate Health Appoints CEO to Lead Commercial Expansion

May 5, 2025 11:00 AM

Genomate Health, a precision oncology company developing a new category of computational tools for Digital Drug Assignment (DDA) - a method using advanced computational reasoning to automatically match the most effective and personalized drug treatment to an individual patient's unique biological and clinical profile - announced today a major step in its growth with the appointment of a new CEO.Built to support oncologists in selecting the right...

Read more

Enhancing Patient Access: Penn Medicine Becker ENT & Allergy Launches New Berlin Rd Facility in Voorhees, NJ

May 5, 2025 8:00 AM

Penn Medicine Becker ENT & Allergy is pleased to announce the opening of its new facility on Berlin Road in Voorhees, NJ. This newest location is designed to provide comprehensive, patient-centered ear, nose, throat (ENT) and allergy services in a welcoming environment. The expansion builds on the group's long-standing commitment to delivering accessible, high-quality care and aims to serve an even broader patient base across the region.A Legacy...

Read more

Advanced Recovery: EMS and Decompression Therapy Benefits

May 5, 2025 6:00 AM

Recovery these days in the fast-paced world is not only about rest but innovation. Physiotherapy too has seen a sea of change with the inclusion of technology-based therapies that go beyond manual therapies. Among the most promising developments are EMS therapy Dubai and Decompression therapy (Vertonex), two cutting-edge methods now available at Physiowell in Dubai. Both of them, together, bring a powerful synergy to accelerate healing, reduce...

Read more

Leading Proxy Advisory Firm Egan-Jones Recommends Stockholders Vote "FOR" All National Health Investors' Director Nominees

May 5, 2025 6:00 AM

National Health Investors, Inc. (NYSE:NHI) ("NHI" or "the Company") today announced that leading proxy advisory firm Egan-Jones has recommended that stockholders vote on the WHITE proxy card "FOR" ONLY NHI's director nominees - Candice W. Todd, Robert W. Chapin, Jr., James R. Jobe and Robert G. Adams - in connection with its May 21, 2025 Annual Meeting of Stockholders (the "Annual Meeting").In summarizing its position, Egan-Jones stated:"NHI has...

Read more

BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization

May 5, 2025 3:05 AM

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its first national level patent filing has been accepted by the Eurasian Patent Organization (EAPO). The EAPO has confirmed the Company‘s core patent claims, namely: novelty, inventive step, and industrial applicability.BioNxt's flagship patent filing, which...

Read more

AlzeCure Publishes its Interim Report for January - March 2025

May 5, 2025 2:20 AM

AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - March 2025 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/"The first quarter of 2025 was yet another active and eventful quarter for AlzeCure Pharma. In February 2025, we received a grant of EUR 2.5 million from the European Innovation Council...

Read more

DEA Diversion in Cannabis Chaos: MMJ Urges Terrance Cole, President Trump DEA Nominee to Dismantle Biden Era Cannabis Obstructors

May 4, 2025 5:00 AM

MMJ BioPharma Cultivation announced it will file an emergency motion and lawsuit in the U.S. District Court for the District of Rhode Island following a controversial ruling by DEA Administrative Law Judge (ALJ) Teresa Wallbaum. Judge Wallbaum recently issued a ruling to vacate a previously granted stay-clearing the path for a DEA ALJ hearing before what MMJ asserts is a constitutionally defective tribunal. Judge Wallbaum retired immediately...

Read more